Global distribution agreement with Bruker for COVID-19 diagnostic test COVID-19 test receives FDA approval in the Philippines

Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that Primerdesign, its molecular diagnostics division, has signed a global distribution agreement for its COVID-19 test with Bruker-Hain Diagnostics, the molecular diagnostics products business unit of Bruker Corporation (Bruker). http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update_Bruker-ENGLISH-25.03.20.pdf

Visit Page

Contract manufacturing services agreement signed with Yourgene Health Plc Additional manufacturing capacity to support demand for Novacyt’s COVID-19 diagnostic test

Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.

Visit Page

US FDA Emergency Use Authorization for COVID-19 diagnostic test COVID-19 RUO test receives approval in Indonesia

Paris, France and Camberley, UK – 23 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test. As a result, hospitals and laboratories in the US will

Visit Page

Mise à jour sur le test pour le coronavirus Augmentation significative de la demande Poursuite de l’expansion des capacités de production

Paris, France et Camberley, Royaume-Uni – 20 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir de faire le point sur le nouveau test de détection du coronavirus (COVID-19) mis au point par Primerdesign, sa division de diagnostic moléculaire basée au Royaume-Uni. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-mise-à-jour-sur-le-test-pour-le-coronavirus-FRENCH-20.03.20.pdf

Visit Page

Coronavirus test update Significant increase in demand Further expansion of manufacturing capacity

Paris, France and Camberley, UK – 20 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update-ENGLISH-20.03.20-Final.pdf

Visit Page

Coronavirus test update Initial orders from Public Health England

Paris, France and Camberley, UK – 16 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update-ENGLISH-16.03.20.pdf

Visit Page

Mise à jour sur le test pour le coronavirus Première commande de Public Health England

Paris, France et Camberley, Royaume-Uni – 16 mars 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer de nouveaux développements pour son test pour le nouveau coronavirus (COVID-19) développé par Primerdesign, sa division de diagnostic moléculaire. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-mise-à-jour-sur-le-test-pour-le-coronavirus-FRENCH-16.03.20.pdf

Visit Page

Coronavirus test update Investment in manufacturing capacity

Paris, France and Camberley, UK – 12 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division, and announces it has invested in a significant increase in manufacturing capacity to support

Visit Page

Mise à jour sur le test pour le coronavirus Investissement dans les capacités de production

Paris, France et Camberley, Royaume-Uni – 12 mars 2020 –Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, a le plaisir d’annoncer de nouveaux développements pour son test pour le nouveau coronavirus (COVID-19) développé par Primerdesign, sa division de diagnostic moléculaire, et d’avoir investi pour accroitre significativement sa capacité de production afin de répondre

Visit Page

Information mensuelle le contrat de liquidité et sur le nombre total de droits de vote

Paris, France et Camberley, Royaume-Uni – 2 mars 2020 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), un spécialiste international du diagnostic clinique, publie aujourd’hui le bilan mensuel du nombre d’actions échangées au titre du contrat de liquidité confié à Invest Securities SA (le « Contrat de liquidité »). Le contrat de liquidité est régi par le droit français

Visit Page